CNV2197944: Phase I data

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) reported data from a placebo-controlled, U.K. Phase I trial in healthy volunteers showing that multiple ascending-doses of oral CNV2197944 were well...